Atypical autoimmune adverse effects with checkpoint blockade therapies

Ann Oncol. 2017 Feb 1;28(2):206-207. doi: 10.1093/annonc/mdw658.

Authors

C F Friedman^{1

2}, A Snyder^{1

2}

Affiliations

¹ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York.
² Weill Cornell Medical College, New York, USA.

PMID: 27993802
DOI: 10.1093/annonc/mdw658

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal / adverse effects*
Antibodies, Monoclonal / immunology
Antibodies, Monoclonal / therapeutic use
Antineoplastic Agents, Immunological / adverse effects*
Antineoplastic Agents, Immunological / immunology
Antineoplastic Agents, Immunological / therapeutic use
B7-H1 Antigen / antagonists & inhibitors
B7-H1 Antigen / immunology
CTLA-4 Antigen / antagonists & inhibitors
CTLA-4 Antigen / immunology
Humans
Immune System Diseases / chemically induced*
Immune System Diseases / immunology
Immunotherapy / adverse effects
Immunotherapy / methods
Neoplasms / drug therapy
Neoplasms / immunology
Programmed Cell Death 1 Receptor / antagonists & inhibitors
Programmed Cell Death 1 Receptor / immunology

Substances

Antibodies, Monoclonal
Antineoplastic Agents, Immunological
B7-H1 Antigen
CD274 protein, human
CTLA-4 Antigen
CTLA4 protein, human
PDCD1 protein, human
Programmed Cell Death 1 Receptor